Antibody therapeutics:
- 29 August 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 7 (9) , 1401-1413
- https://doi.org/10.1517/14712598.7.9.1401
Abstract
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of sol...Keywords
This publication has 90 references indexed in Scilit:
- Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodiesMolecular Immunology, 2007
- Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systemsProceedings of the National Academy of Sciences, 2006
- Isolation and analysis of a baculovirus vector that supports recombinant glycoprotein sialylation by SfSWT‐1 cells cultured in serum‐free mediumBiotechnology & Bioengineering, 2006
- Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levelsNature Biotechnology, 2005
- FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemiaBlood, 2005
- Generation of Arabidopsis thaliana plants with complex N‐glycans lacking β1,2‐linked xylose and core α1,3‐linked fucoseFEBS Letters, 2004
- Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural IntegrityPublished by Elsevier ,2003
- The structural requirements for complement activation by IgG: does it hinge on the hinge?Immunology Today, 1995
- Human IgG subclass pattern of inducing complement‐mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentrationEuropean Journal of Immunology, 1991
- Human IgG Fc receptorsClinical Immunology and Immunopathology, 1989